ASCO's 2026 theme, The Science and Practice of Translation: Improving Cancer Outcomes Worldwide, proved particularly fitting this year.
The meeting showcased some of the most exciting scientific advances oncology has seen in years, from pan-RAS inhibitors in pancreatic cancer to a growing wave of antibody-drug conjugates (ADCs), bispecific antibodies, and increasingly sophisticated biomarker-driven approaches. Yet one message emerged repeatedly across scientific sessions, investigator discussions, and industry conversations: scientific innovation alone is no longer the industry's biggest challenge.
The question facing sponsors today is how to translate these advances into treatments that can reach patients globally.
Historically, translational science has described the process of moving discoveries from the laboratory into the clinic. ASCO 2026 demonstrated that this definition is expanding. The next era of translation is not only about connecting bench research to patient care, but also about bridging geographies, healthcare systems, and patient populations so that innovation developed in one part of the world can benefit patients everywhere.
Scientific Innovation Continues to Accelerate
One of the most closely watched developments at this year's meeting was the emergence of Phase III data for pan-RAS inhibitors in pancreatic ductal adenocarcinoma (PDAC).
For decades, RAS was considered undruggable. At the same time, pancreatic cancer has remained one of the most aggressive and treatment-resistant malignancies, with limited advances for patients. The survival benefit demonstrated by daraxonrasib and other emerging pan-RAS approaches represents a significant scientific achievement and has generated understandable excitement across the oncology community.
The enthusiasm is warranted. However, as these therapies move forward, several important questions remain.
Inhibiting wild-type RAS across multiple isoforms presents a narrow therapeutic window, making toxicity management a critical consideration. Gastrointestinal and dermatologic toxicities will need to be carefully monitored to ensure long-term tolerability and patient compliance. As with many targeted therapies, resistance mechanisms will also require close attention. Tumours adapt rapidly, and understanding how resistance emerges—and what subsequent clonal evolution looks like—will be critical to maximizing long-term benefit.
Perhaps most importantly, the discussion is already shifting from monotherapy to combination strategies. The next chapter for pan-RAS development will likely depend as much on trial design and execution as on the underlying science itself.
For sponsors, this creates increasingly complex operational demands. Studies involving rapidly progressing diseases such as PDAC require meticulous site selection, highly experienced clinical teams, and robust safety oversight. As scientific advances become more sophisticated, operational execution becomes increasingly important. Success will depend not only on demonstrating efficacy, but on the ability to manage complex safety profiles, monitor resistance mechanisms, and execute combination studies efficiently.
Innovation Is Becoming Increasingly Global
Another clear theme at ASCO 2026 was the continued globalization of oncology innovation.
The innovation story emerging from China has changed significantly over the past several years. Rather than focusing primarily on biosimilars or fast-followers, many companies are now advancing genuinely novel therapies, particularly in areas such as ADCs, bispecific antibodies, and other advanced biologic platforms.
This shift was evident throughout the meeting.
One of the most discussed examples was the HARMONi-6 trial, which delivered the first Phase III overall survival readout for a China-originated innovative oncology therapy. The positive results for ivonescimab in previously untreated advanced squamous non-small cell lung cancer demonstrated the potential for therapies developed within a single region to address significant unmet needs on a global scale.
At the same time, these results highlighted an increasingly important question for sponsors and regulators alike.
How do we ensure that promising results generated within one country or region can be translated into confidence across broader and more diverse patient populations?
That question surfaced repeatedly in discussions surrounding both late-stage and early-stage programs. Many of the novel agents generating excitement at ASCO have been studied primarily within China or Asia-Pacific populations. While these studies have produced compelling data, the path to global adoption increasingly depends on demonstrating that those benefits extend across different patient populations, healthcare settings, and treatment practices.
Many of the most promising therapies presented at ASCO originated within a single geography. Their ultimate impact, however, will depend on how quickly developers can generate evidence that supports broader adoption. Novel therapies that demonstrate meaningful benefit for patients in one region are often addressing the same unmet needs elsewhere. The challenge for sponsors is no longer simply to develop innovative medicines, but to ensure those innovations can reach patients wherever the need exists.
The Next Stage of Translation
This is where ASCO's theme took on broader meaning.
Translational science can no longer be viewed solely through the traditional lens of laboratory discovery and clinical validation. The industry is moving toward a future where translation also means generating evidence that is globally relevant.
Sponsors are increasingly recognizing that development strategies designed around a single geography may limit future opportunities. Generating globally relevant data across diverse patient populations is becoming a prerequisite for realizing the full value of innovation. The industry has become highly effective at translating scientific discoveries into promising therapies. The next challenge is translating those therapies into globally applicable evidence that can support adoption across different healthcare systems and patient populations.
This thinking is also contributing to a significant shift toward ex-US clinical development strategies. Sponsors are no longer evaluating these approaches as an alternative pathway. Increasingly, they are becoming a core component of development planning, driven by rising trial costs, intense site competition, and recruitment pressures in the United States.
Asia-Pacific remains at the centre of this trend. Countries such as South Korea, Australia, and China continue to attract investment because they combine efficient regulatory pathways, strong clinical infrastructure, experienced investigators, and access to large patient populations. For many sponsors, these advantages can significantly compress early-phase development timelines while supporting the generation of globally relevant data.
A More Disciplined Development Environment
The broader market environment reflected this evolution as well.
Compared with recent years, the overall mood at ASCO was noticeably more optimistic. Capital is flowing back into the sector, but investors remain far more selective than during previous market cycles.
Early-stage biotechnology companies are placing greater emphasis on preserving cash runway and demonstrating clear proof-of-concept before pursuing broader expansion strategies. Platform validation and asset-focused development have become priorities.
Meanwhile, later-stage companies are increasingly focused on reducing execution risk. Their attention is centred on registrational pathways, recruitment predictability, data quality, and selecting operational partners capable of supporting global regulatory submissions.
Across both groups, a common theme emerged: scientific innovation remains essential, but execution is increasingly what determines success. Early-stage companies are seeking the fastest and most efficient route to proof-of-concept, while later-stage organizations are focused on de-risking registrational pathways through predictable recruitment, high-quality data, and operational consistency. In both cases, sponsors are placing greater value on development strategies that reduce uncertainty and accelerate decision-making.
Looking Ahead
The scientific advances presented at ASCO 2026 leave little doubt that oncology innovation is accelerating. From pan-RAS inhibitors to next-generation ADCs, bispecific antibodies, and novel biomarker-driven approaches, researchers continue to expand what is possible for patients with cancer.
Yet the strongest message from this year's meeting may not have been about any single therapeutic breakthrough. It was about the growing importance of translation in its broadest sense.
Translational science is no longer confined to moving discoveries from the laboratory into the clinic. Increasingly, it involves bridging geographies, healthcare systems, and patient populations to ensure that promising therapies can generate evidence that is relevant on a global scale.
The industry has become highly effective at creating innovation. The next challenge is ensuring that innovation reaches the patients who need it, regardless of where they live. Achieving that will require not only scientific excellence, but also thoughtful development strategies, diverse patient populations, and operational execution capable of turning promising science into globally meaningful outcomes.
To discuss what this means for your development strategy, connect with a Novotech expert. https://novotech-cro.com/talk-to-an-expert